| Literature DB >> 23799955 |
Suriana Sabri1, Jennifer A Steen, Mareike Bongers, Lars K Nielsen, Claudia E Vickers.
Abstract
BACKGROUND: Metabolic engineering projects often require integration of multiple genes in order to control the desired phenotype. However, this often requires iterative rounds of engineering because many current insertion approaches are limited by the size of the DNA that can be transferred onto the chromosome. Consequently, construction of highly engineered strains is very time-consuming. A lack of well-characterised insertion loci is also problematic.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23799955 PMCID: PMC3706339 DOI: 10.1186/1475-2859-12-60
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Figure 1Location of KIKO target loci on the genome of MG1655. Map generated using the Microbial Genome Viewer (http://mgv2.cmbi.ru.nl; [47]). Locus positions relative to oriC are conserved in E. coli W. Arrows represent gene orientation.
Figure 2Generic features of the KIKO plasmids and integration protocol. A) Map of the general features of the KIKO vectors, showing the location of the antibiotic resistance cassettes (ApR, ampicillan resistance; KmR, kanamycin resistance; CmR, chloramphenicol resistance), the flippase recombinase target sites (FRT), the hairpin loops (HL), the homologous arms (HA1 and HA2) used for recombination onto the E. coli chromosome and the unique restriction sites located within the multiple cloning site (MCS). B) Process for the isolation of integration mutants. This represents the fastest possible generation protocol by standard cloning; in practice, strain construction is often delayed be a few days for quality control (QC). Strain construction can be shortened by two days if insertion cassettes are constructed by Gibson assembly.
Figure 3Specific growth rate (μ; hr) of engineered strains. The growth rate of E. coli K-12 (MG1655) and W strains harbouring exogenous DNA integrated into various different loci was measured on LB medium in the absence of selection to allow comparison with wild type strains. Bars are means; errors are standard deviations (n = 3). No significant differences were identified for either strain (1-way ANOVA; p>0.05).
Figure 4Xylanase assay. Xylanase activity was measured in extracts from E. coli K-12 (MG1655) and W strains harbouring xynA integrated into various different loci. Xylanase is expressed in relative fluorescence units (RFU) per minute per mg protein. Bars represent means; errors are standard deviations (n = 3). One-way ANOVA followed by Tukey’s HSD post-hoc analysis was used to resolve differences in means; *, p<0.05, **, p<0.01, ***, p<0.001.
Figure 5Sucrose utilisation and GFP activity in strain MGΔ::Δ::Δ::. A) MacConkey agar supplemented with 1% sucrose was used to examine sucrose fermentation in wild type MG1655 (left) and engineered strain MGΔlacZ::xyn ΔrbsAR::gfp ΔarsB::csc. The ability to utilise sucrose is indicated by a pH change resulting from fermentation products; this is evidenced by red colonies on the MacConkey sucrose plate. B) Wild type MG1655 exhibits no fluorescence in the presence of UV light (left), whereas the engineered strain MGΔlacZ::xyn ΔrbsAR::gfp ΔarsB::csc fluoresces bright green (right).
Direct comparison of integration using linearised plasmid and pcr products
| W | Plasmid | 38 | 33 | 2 | 3 | 92% | |
| PCR | 2 | 0 | 2 | 0 | 100% | ||
| MG1655 | Plasmid | 38 | 4 | 15 | 19 | 50% | |
| PCR | 14 | 0 | 2 | 12 | 14% | ||
| W | Plasmid | 8 | 5 | 1 | 2 | 75% | |
| PCR | 6 | 0 | 1 | 5 | 17% | ||
| MG1655 | Plasmid | 32 | 25 | 6 | 1 | 97% | |
| PCR | 39 | 5 | 12 | 22 | 44% | ||
| W | Plasmid | 22 | 0 | 16 | 6 | 73% | |
| PCR | 7 | 0 | 5 | 2 | 71% | ||
| MG1655 | Plasmid | 8 | 0 | 8 | 0 | 100% | |
| PCR | 15 | 0 | 14 | 1 | 93% |
Templates for each transformation (linearised plasmid or PCR) are noted, as well as the number of colonies obtained from each transformation, the number of colonies having a wild type locus (no integration), the number of colonies having a single cross-over (Single X; integration of entire plasmid) and the number of colonies having a double cross-over (Double X; integration of only the region contained between the homologous arms). Background % is calculated based on the number of WT locus + Single X colonies.
Strains used in this study
| BW23474 | Δ | [ |
| MG1655 | λ-, rph-1 | CGSC1 |
| MGΔ | MG1655 | This study |
| MGΔ | MG1655 | This study |
| MGΔ | MG1655 | This study |
| MGΔ | MG1655 | This study |
| MGΔ | MG1655 | This study |
| MGΔ | MG1655 Δ | This study |
| MGΔ | MG1655 Δ | This study |
| MGΔ | MG1655 Δ | This study |
| W | Wild type strain | NCIMB 86662 |
| WΔ | W | This study |
| WΔ | W | This study |
| WΔ | W | This study |
1Purchased from the Coli Genetic Stock Centre (CGSC).
2National Collection of Industrial Bacteria, Aberdeen, Scotland. This strain is also archived as ATCC9637 in the American Type Culture Collection.
Plasmids used in this study
| pKD3 | oriR6Kgamma | [ |
| pKD4 | oriR6Kgamma | [ |
| pKD46 | repA101ts & oriR101 ParaB | [ |
| pCP20 | Flp recombinase expression plasmid | [ |
| pNPDX2 | PBTac2 (Boehringer) carrying modified | [ |
| pBAV1K-T5-gfp | pBAV1K-T5 plasmid that carries | [ |
| pCSCX | pCR2.1 plasmid carrying | [ |
| pJAS01 | Synthetic construct. Contains MCS & FRT- | This study |
| p | JSP64/JSP65 PCR product from pKD4 (PvuII; 1,495; R6K | This study |
| p | JSP64/JSP65 PCR product from pKD4 (PvuII; 1,495; R6K | This study |
| p | JSP64/JSP65 PCR product from pKD4 (PvuII; 1,495; R6K | This study |
| pKIKO | p | This study |
| pKIKO | p | This study |
| pKIKO | p | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
| pKIKO | pKIKO | This study |
Primers used in this study
| JSP10 | Amplification of | GGCGCAGCT |
| JSP11 | Amplification of | GGGTCAGCT |
| JSP22 | Screening oligo for KIKO vector inserts | TTCTGCGAAGTGATCTTCCG |
| JSP55 | Amplification of | GCGA |
| JSP56 | Amplification of | GCGA |
| JSP57 | Amplification of | GCGA |
| JSP58 | Amplification of | GCGA |
| JSP64 | Amplification of R6K ori and | TAGGC |
| JSP65 | Amplification of R6K ori and | CCCCC |
| JSP123 | Confirmation of | CAACCTGGCTCGACAAAACT |
| JSP124 | Confirmation of | GTGTCACAAACAGCACAGGC |
| JSP125 | Confirmation of | CCGAACTGATGAAAGTGCTC |
| JSP126 | Confirmation of | GCGTAAATCTAAGCCGAACC |
| JSP129 | Confirmation of | GTCTGAATTTGACCTGAGCG |
| JSP130 | Confirmation of | TCATACAGAACTGGCGATCG |
| JSP148 | Amplification of | AGGA |
| JSP149 | Amplification of | AAAC |
| cscB_F2 | Screening oligo for | ATGGCACTGAATATTCCATTCAGA |
| KO Test | Confirmation of insertion junction at Cm end | GGAGTGAATACCACGACGAT |
Restriction enzyme sites included in primers are underlined, and the enzyme name is listed in the Application column.
List of kiko vectors, their characteristics and genbank accession numbers
| pKIKO | KC503965 | ||
| pKIKO | KC503966 | ||
| pKIKO | KC503967 | ||
| pKIKO | KC503968 | ||
| pKIKO | KC503969 | ||
| pKIKO | KC503970 |
The resistance gene listed is the gene inserted onto the chromosome after homologous recombination. Km kanamycin resistance, Cm chloramphenicol resistance.